Cantor Fitzgerald Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $211.00

Share on StockTwits

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective raised by research analysts at Cantor Fitzgerald from $175.00 to $211.00 in a research report issued on Friday, BenzingaRatingsTable reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 53.62% from the company’s previous close.

SRPT has been the subject of a number of other reports. Leerink Swann reaffirmed an “outperform” rating and set a $216.00 price target (up from $186.00) on shares of Sarepta Therapeutics in a report on Friday. Credit Suisse Group raised their price target on shares of Sarepta Therapeutics from $185.00 to $190.00 and gave the company an “outperform” rating in a report on Friday. BidaskClub lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $215.00 price target on shares of Sarepta Therapeutics in a report on Friday. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a report on Tuesday, October 8th. Two equities research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $192.63.

Shares of Sarepta Therapeutics stock traded up $36.88 during trading hours on Friday, hitting $137.35. The company’s stock had a trading volume of 7,652,275 shares, compared to its average volume of 1,071,850. Sarepta Therapeutics has a 1-year low of $72.05 and a 1-year high of $158.80. The business has a fifty day moving average of $99.24 and a 200 day moving average of $110.97. The company has a market capitalization of $7.56 billion, a PE ratio of -25.16 and a beta of 2.30. The company has a quick ratio of 5.54, a current ratio of 6.31 and a debt-to-equity ratio of 0.49.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.35). Sarepta Therapeutics had a negative return on equity of 55.44% and a negative net margin of 169.87%. The business had revenue of $99.04 million during the quarter, compared to analyst estimates of $98.49 million. During the same period in the previous year, the company earned ($1.15) EPS. Sarepta Therapeutics’s revenue was up 26.2% on a year-over-year basis. On average, sell-side analysts anticipate that Sarepta Therapeutics will post -6.02 earnings per share for the current fiscal year.

In other Sarepta Therapeutics news, EVP David T. Howton sold 25,000 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $105.00, for a total transaction of $2,625,000.00. Following the transaction, the executive vice president now directly owns 24,388 shares in the company, valued at approximately $2,560,740. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 6.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. Point72 Asset Management L.P. bought a new position in Sarepta Therapeutics during the 3rd quarter valued at $52,474,000. Price T Rowe Associates Inc. MD lifted its position in shares of Sarepta Therapeutics by 10.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,902,227 shares of the biotechnology company’s stock worth $592,943,000 after buying an additional 359,160 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Sarepta Therapeutics by 363.3% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 405,332 shares of the biotechnology company’s stock worth $30,530,000 after buying an additional 317,840 shares during the last quarter. Nuveen Asset Management LLC lifted its position in shares of Sarepta Therapeutics by 1,074.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 310,174 shares of the biotechnology company’s stock worth $47,131,000 after buying an additional 283,766 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Sarepta Therapeutics by 3.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,232,424 shares of the biotechnology company’s stock worth $947,017,000 after buying an additional 232,752 shares during the last quarter. Hedge funds and other institutional investors own 97.78% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Further Reading: Sell-Side Analysts

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
PNM Resources Inc  Shares Sold by James Investment Research Inc.
PNM Resources Inc Shares Sold by James Investment Research Inc.
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc


© 2006-2020 Ticker Report